Julien Dilly

This study shows that KRASG12C inhibitors alter the surface proteome of lung cancer cells, revealing FOLR1 as a new target when combined with an antibody drug conjugate.

This study identifies Glis3 as a key transcription factor driving metastasis in PDAC by promoting a neural-like progenitor cell state.

This study uses deep mutational scanning to analyze KRAS variants, identifying gain- and loss-of-function mechanisms and their impact on oncogenic activity.

This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.

The paper identifies adeno-to-squamous transition (AST) as a mechanism of resistance to KRAS inhibitors in LKB1 mutant lung cancer and links KRT6A expression to poor patient outcomes.